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1,2
Objectives: To report updated longer-term secukinumab exposure safety data from PsO and PsA studies (data cut-off: 25 June 2016). Methods: The PsO data pool consisted of 9 Phase III studies in moderate-tosevere plaque PsO and PsA pool consisted of 3 Phase III studies in active PsA. Secukinumab doses differed in the studies and included intravenous (up to 10 mg/kg) or subcutaneous (s.c.; 75-300 mg) loading, followed by s.c. maintenance dosing (300, 150 or 75 mg). Placebo patients were re-randomised to secukinumab at 12-24 weeks depending on study design. Only data for approved secukinumab 300 and 150mg doses were included in analysis. Exposure adjusted incident rates (EAIR) were used to adjust for differences in exposure. Results: In both PsO and PsA, the most frequently reported adverse events (AEs) with secukinumab were non-serious infections of the upper respiratory tract, headache and arthralgia (Table) . The EAIRs of AEs of special interest with secukinumab including Crohn's disease, Candida infections, serious infections, inflammatory bowel disease, major adverse cardiac events and neutropenia (reported in the Table) were similar in both PSO and PsA indications, and comparable to those reported previously.
1,2 No cases of tuberculosis (new onset or reactivation) were reported. 1 Adverse events in the secukinumab group that occurred with an IR >5.0 during the entire safety period in either of the spooled groups; AE, adverse event; EAIR, exposure adjusted incidence rate per 100 patient-years; MACE, major adverse cardiac event; N, number of patients in the analysis.
Conclusions:
The safety profile of secukinumab was similar for PsO and PsA patients supporting its long-term use in these chronic conditions. Secukinumab long-term exposure safety data is consistent with that previously reported with shorter-term exposure, including being well tolerated, and without any new safety signals identified. 
